Trial · NCT00338598

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

NCT00338598, Phase 2, Completed, Yale University; results first posted 2017-04-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism. Trials, record NCT00338598. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00338598

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
NCT number: NCT00338598
Status: Completed
Phases: Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Yale University
Conditions: Alcoholism, Schizophrenia
Interventions: Glycine, placebo
First posted: 2006-06-20
Last updated: 2018-01-17
Results first posted: 2017-04-12

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Self Reported Weekly Alcohol Consumption	12 weeks	Percentage of drinking days and heavy drinking days using timeline follow back
Primary	Self Reported Weekly Alcohol Craving	12 weeks	The Obsessive Compulsive Drinking Scale (OCDS) is consisted by 14 items rated 0 - 4. The minimum and maximum values possibly obtained in this scale are respectively 0 and 56, this last one, meaning the most craving possible experienced. It is a short and easy to administer scale (average of 5 minutes per self-rating), built to measure severity and improvement during alcoholism treatment trials.
Primary	Weekly Ratings of Negative/Positive Psychotic Symptoms	12 weeks	The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale.The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. A higher score indicates more severe symptoms for each scale.
Primary	Baseline and End of Treatment Cognitive Functioning Measures (Hopkins)	12 weeks	Hopkins Verbal Learning Test Assesses short term verbal learning and memory. Subscales include immediate recall (0-36), delayed recall (0-12) , and recognition (0-12). A higher score indicates better memory performance.
Secondary	Weekly Drug Use	12 weeks
Secondary	Baseline and End of Treatment Quality of Life	12 weeks
Secondary	Baseline and End of Treatment Neurophysiological Measures	12 weeks

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Self Reported Weekly Alcohol Consumption	12 weeks		percentage of days	MEAN
PRIMARY	Self Reported Weekly Alcohol Craving	12 weeks		units on a scale	MEAN
PRIMARY	Weekly Ratings of Negative/Positive Psychotic Symptoms	12 weeks		units on a scale	MEAN
PRIMARY	Baseline and End of Treatment Cognitive Functioning Measures (Hopkins)	12 weeks		units on a scale	MEAN
SECONDARY	Weekly Drug Use	12 weeks	Data was not collected
SECONDARY	Baseline and End of Treatment Quality of Life	12 weeks	Data was not collected
SECONDARY	Baseline and End of Treatment Neurophysiological Measures	12 weeks	Data was not collected

Source ClinicalTrials.gov

Results by group32

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Self Reported Weekly Alcohol Consumption	Glycine	% number of drinking days	23.4	Standard Error 28.8	percentage of days
Self Reported Weekly Alcohol Consumption	Placebo	% number of drinking days	19.6	Standard Error 29.0	percentage of days
Self Reported Weekly Alcohol Consumption	Glycine	% number of heavy drinking days	15.7	Standard Error 20.8	percentage of days
Self Reported Weekly Alcohol Consumption	Placebo	% number of heavy drinking days	10.0	Standard Error 12.6	percentage of days
Self Reported Weekly Alcohol Craving	Glycine	Baseline	16.1	Standard Error 3.1	units on a scale
Self Reported Weekly Alcohol Craving	Placebo	Baseline	17.5	Standard Error 3.2	units on a scale
Self Reported Weekly Alcohol Craving	Glycine	Week 12	10.2	Standard Error 3.1	units on a scale
Self Reported Weekly Alcohol Craving	Placebo	Week 12	12.1	Standard Error 3.3	units on a scale
Weekly Ratings of Negative/Positive Psychotic Symptoms	Glycine	Baseline Positive	16.3	Standard Error 1.3	units on a scale
Weekly Ratings of Negative/Positive Psychotic Symptoms	Placebo	Baseline Positive	15.3	Standard Error 1.3	units on a scale

1 to 10 of 32Source ClinicalTrials.gov

See all 32 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Glycine	10
Overall Study	STARTED	Placebo	10
Overall Study	COMPLETED	Glycine	10
Overall Study	COMPLETED	Placebo	8
Overall Study	NOT COMPLETED	Glycine	0
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	ER for intoxication	General disorders	Glycine	0	10
other	ER for intoxication	General disorders	Placebo	1	10
other	Chest Pain	Respiratory, thoracic and mediastinal disorders	Glycine	0	10
other	Chest Pain	Respiratory, thoracic and mediastinal disorders	Placebo	1	10
other	ER Visit	General disorders	Glycine	1	10
other	ER Visit	General disorders	Placebo	0	10
other	Diarrhea	Gastrointestinal disorders	Glycine	1	10
other	Diarrhea	Gastrointestinal disorders	Placebo	0	10
other	Vomiting	Gastrointestinal disorders	Glycine	1	10
other	Vomiting	Gastrointestinal disorders	Placebo	0	10

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Glycine	0	10
Total, all-cause mortality	Placebo	0	10
Total, other adverse events	Glycine	3	10
Total, other adverse events	Placebo	2	10
Total, serious adverse events	Glycine	0	10
Total, serious adverse events	Placebo	0	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Glycine vs Placebo: deaths from any cause	Trial comparisons
Glycine vs Placebo: serious adverse events	Trial comparisons

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Verbal Learning	Primary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00338598

GET https://conductscience.org/api/trials/v1/NCT00338598/results?page=2

API reference For AI assistants